新型冠状病毒肺炎疫苗接种后无周期性血管性水肿伴嗜酸性粒细胞增多症：一例用瑞利珠单抗成功治疗的病例
Nonepisodic angioedema with eosinophilia after COVID-19 vaccination: a case successfully treated with reslizumab.
作者信息
Nam Young-Hee
机构信息
Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
出版信息
Allergy Asthma Clin Immunol. 2023 Feb 2;19(1):11. doi: 10.1186/s13223-023-00765-8.
BACKGROUND
Angioedema with eosinophilia (AE) is a rare allergic disease classified as episodic or nonepisodic. AE is characterized by angioedema, urticaria, fever, weight gain, and eosinophilia, but its etiology and pathogenesis have not yet been clarified.
CASE PRESENTATIONS
We present a 70-year-old woman presented with generalized edema and urticaria after Moderna COVID-19 vaccination. Peripheral blood eosinophil count was marked elevated and echocardiography and Doppler ultrasonography of both the upper and lower extremities were unremarkable. Her symptoms and peripheral blood eosinophil count were improved after systemic steroid therapy, but she failed to respond to steroid tapering. Reslizumab (anti-interluekin-5) was administered intravenously, and she remained symptom free with a normal eosinophil count during 8 months of reslizumab treatment without steroids.
CONCLUSIONS
We report a case of nonepisodic AE after COVID-19 vaccination that was successfully treated with reslizumab.
背景
嗜酸性粒细胞增多性血管性水肿（AE）是一种罕见的过敏性疾病，分为发作性或非发作性。AE的特征为血管性水肿、荨麻疹、发热、体重增加和嗜酸性粒细胞增多，但其病因和发病机制尚未阐明。
病例报告
我们报告一名70岁女性，在接种Moderna新冠疫苗后出现全身性水肿和荨麻疹。外周血嗜酸性粒细胞计数显著升高，上下肢超声心动图和多普勒超声检查未见异常。全身类固醇治疗后，她的症状和外周血嗜酸性粒细胞计数有所改善，但减停类固醇时反应不佳。静脉注射瑞利珠单抗（抗白细胞介素-5）后，在8个月的瑞利珠单抗治疗期间，未使用类固醇，她症状消失，嗜酸性粒细胞计数正常。
结论
我们报告了1例新冠疫苗接种后非发作性AE病例，该病例通过瑞利珠单抗成功治愈。
Zotero 插件